ITIM receptors:more than just inhibitors of platelet activation by Coxon, Carmen H et al.
 
 
University of Birmingham
ITIM receptors
Coxon, Carmen H; Geer, Mitchell J; Senis, Yotis A
DOI:
10.1182/blood-2016-12-720185
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Coxon, CH, Geer, MJ & Senis, YA 2017, 'ITIM receptors: more than just inhibitors of platelet activation', Blood,
vol. 129, no. 26, pp. 3407-3418. https://doi.org/10.1182/blood-2016-12-720185
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Final Version of Record available at: https://doi.org/10.1182/blood-2016-12-720185
Checked 30/5/2017
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
1 
ITIM receptors: more than just inhibitors of platelet activation 
Carmen H. Coxon
1
, Mitchell J. Geer
2
 and Yotis A. Senis
2
 
1
Target Discovery Institute, NDM Research Building, University of Oxford, Old Road 
Campus, Headington, OX3 7FZ 
2
Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of 
Birmingham, Birmingham, United Kingdom B15 2TT 
C.H.C. and M.J.G. contributed equally 
 
Abstract length: 248 
Manuscript length: 4,897 
Number of Figures: 5 
Number of Supplementary Figures: 1 
Number of Tables: 3 
Number of References: 88 
 
Key Points 
Platelets express a variety of ITIM-containing receptors, each of which plays a unique role in 
regulating platelet function. 
ITIM-containing receptors do more than inhibit ITAM-containing receptor signaling in 
platelets.   
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Abstract 
Since their discovery, immunoreceptor tyrosine-based inhibition motif (ITIM)-containing 
receptors have been shown to inhibit signaling from immunoreceptor tyrosine-based 
activation motif (ITAM)-containing receptors in almost all hematopoietic cells, including 
platelets.  However, a growing body of evidence has emerged demonstrating that this is an 
over-simplification, and that ITIM-containing receptors are versatile regulators of platelet 
signal transduction, with functions beyond inhibiting ITAM-mediated platelet activation.  
PECAM-1 was the first ITIM-containing receptor identified in platelets and appeared to 
conform to the established model of ITIM-mediated attenuation of ITAM-driven activation. 
PECAM-1 was therefore widely accepted as a major negative regulator of platelet activation 
and thrombosis for many years, but more recent findings suggest a more complex role for this 
receptor, including the facilitation of IIb3-mediated platelet functions.  Since the 
identification of PECAM-1, several other ITIM-containing platelet receptors have been 
discovered.  These include G6b-B, a critical regulator of platelet reactivity and production, 
and the non-canonical ITIM-containing receptor TLT-1, which is localized to -granules in 
resting platelets, binds fibrinogen, and acts as a positive regulator of platelet activation.  
Despite structural similarities and shared binding partners, including the Src homology 2 
domain-containing protein-tyrosine phosphatases Shp1 and Shp2, knockout and transgenic 
mouse models have revealed distinct phenotypes and non-redundant functions for each ITIM-
containing receptor in the context of platelet homeostasis.  These roles are likely influenced 
by receptor density, compartmentalization, and as yet unknown binding partners.  In this 
review, we discuss the diverse repertoire of ITIM-containing receptors in platelets, 
highlighting intriguing new functions, controversies and future areas of investigation. 
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Introduction 
Platelets are small anucleate fragments derived from megakaryocytes that are vital for 
maintaining hemostasis.  A growing body of evidence has established that platelets also 
contribute to other pathophysiological processes, including atherogenesis,
1
 inflammation,
2
 
wound repair,
3
 angiogenesis,
4
 blood-lymphatic vessel separation
5
 and cancer metastasis.
6
  A 
common underlying theme is that platelets must transition from a ‘resting’ to an ‘activated’ 
state to contribute to each of these processes.  Thus, understanding how platelets undergo this 
transition has broad implications for a number of diseases. 
Taking thrombosis and hemostasis as a paradigm of platelet activation, transition from 
the resting state relies on key receptors coming into contact with their cognate ligands in the 
vessel wall and transmitting activation signals within platelets.  Once adhered, thrombus 
formation is initiated and shaped accordingly to minimize blood loss, whilst maintaining 
blood flow.  Tyrosine kinase-linked receptors (TKLRs), including the von Willebrand factor 
(vWF) receptor complex glycoprotein (GP)Ib-IX-V and the integrins IIb3 and 21 play 
critical roles in the initial tethering, adhesion and activation of platelets at sites of injury.  
More robust activation is provided by the immunoreceptor tyrosine-based activation motif 
(ITAM)-containing collagen receptor complex GPVI-FcR -chain,7 collagen-mediated 
clustering of which leads to phosphorylation of tyrosine residues within the FcR -chain 
ITAM by Src family kinases (SFKs).  The Src homology 2 (SH2) domain-containing protein-
tyrosine kinase (PTK) Syk can then be recruited and propagate the signal through tyrosine 
phosphorylation and a rise in intracellular Ca
2+
.  The cellular consequences of these series of 
biochemical events is the release of secondary mediators, including adenosine diphosphate 
(ADP) and thromboxane A2 (TxA2), integrin activation and procoagulant activity.  Secondary 
signals provided by the G protein-coupled receptors (GPCRs) for ADP (P2Y1 and P2Y12), 
TxA2 (TP) and thrombin (PAR-1 and PAR-4), synergize with initiating signals from TKLRs 
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to maximally activate platelets and coordinate the platelet response with the coagulation 
system.   
Equally important, but less well understood, are the mechanisms that prevent 
unwarranted platelet activation and limit thrombus size.  Under normal physiological 
conditions platelets are maintained in a resting state by transient inhibitory signals that 
prevent unnecessary activation, whilst at the same time allowing platelets to fully respond to 
vascular injury when required.  Two of the most powerful platelet inhibitors are prostacyclin 
(PGI2) and nitric oxide (NO), which are released by healthy endothelium.  They act by 
elevating intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP) levels in the platelet via adenylate cyclase and soluble guanylate 
cyclase, respectively.  These cyclic nucleotides in turn activate protein kinase A (PKA) and 
PKG, respectively, which phosphorylate key targets and inhibit platelet activation (Figure 1).
8
 
Immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptors provide 
a more specialized, cell-intrinsic inhibition, compared with PGI2 and NO, by primarily 
targeting ITAM-containing receptors (Figure 2).  The prototype of this family of receptors is 
the immune receptor FcRIIB, which inhibits signaling from the ITAM-containing B cell 
receptor complex following ligand-mediated co-clustering of the two receptors.
9
  Structurally, 
all ITIM-containing receptors belong to the immunoglobulin receptor superfamily, and carry 
at least one consensus ITIM sequence in their cytoplasmic tail, defined as I/V/LxYxxL/V (x 
represents any amino acid), in reference to the previously described ITAM (consensus 
sequence YxxI/Lx6-12YxxI/L).
10
  Whereas tyrosine phosphorylation of ITAMs provides 
docking sites for SH2 domain-containing Syk and the structurally-related PTK Zap70 in 
immune cells, tyrosine phosphorylation of ITIMs provides docking sites for SH2 domain-
containing lipid- or protein-tyrosine phosphatases (PTPs), including SHIP-1, Shp1 and Shp2.  
The canonical mode of action of ITIM-containing receptors is positioning phosphatases in 
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close proximity to ITAM-containing receptors, such that the phosphatases are able to 
dephosphorylate and inactivate key components of the ITAM-containing receptor signaling 
pathway (Figure 2).   
A third ITIM-like motif, termed an immunoreceptor tyrosine-based switch motif 
(ITSM, consensus sequence TxYxxV/I),
11
 was subsequently described that confers activating 
and/or inhibitory properties to a receptor, depending on the associated signaling proteins.  
ITSMs were first identified in the signaling lymphocyte adhesion molecule (SLAM) CD150, 
which has both activating and inhibitory functions.
12
  SLAM family proteins recruit members 
of the SLAM-adaptor protein (SAP) family, an interaction that is enhanced, but not 
dependent on, ITSM phosphorylation.
13
  When SAP proteins associate with SLAM family 
receptors activating signals generally predominate, through recruitment of SFKs, whilst the 
absence of SAP adaptors allows phosphatase recruitment to promote inhibitory signaling.
13
  
The abundance and availability of the SAP adaptors adds a layer of complexity to ITSM-
mediated control of SLAM receptor activity.  ITSMs are often found in close proximity to 
ITIMs, facilitating interactions with SH2 domain-containing phosphatases, and contributing 
to the inhibitory function of ITIM-containing receptors. 
For many years, PECAM-1 (also referred to as CD31) was the only known ITIM-
containing receptor in platelets.
14-17
  However, with the advent of proteomics and 
transcriptomics, several other structurally distinct ITIM-containing receptors were identified 
in platelets.  These regulate various aspects of platelet function and include G6b-B,
18,19
 
TREM-like transcript (TLT-1),
20
 carcinoembryonic antigen-related cell adhesion molecule 1 
and 2 (CEACAM1 and CEACAM2)
21,22
 and LILRB2 (also referred to as PIR-B),
23
 structural 
features of which are summarized in Figure 3, and phenotypes of knockout (KO) and 
transgenic mouse models in Table 1.  In addition, the inhibitory collagen-binding ITIM-
containing receptor LAIR-1, also shown in Figure 3, has been identified in immature 
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megakaryocytes, but not mature megakaryocytes or platelets.
24
  Recent work from our group 
has revealed that mice lacking LAIR-1 exhibit a mild thrombocytosis and increased 
proplatelet formation in vitro.
25
  Interestingly, platelets produced by LAIR-1 KO mice exhibit 
an enhanced reactivity to collagen, despite not expressing the receptor, suggesting that effects 
are transmitted from megakaryocytes to platelets.  Two ITSM-containing SLAM family 
members, CD150 and CD84, have been identified in platelets, as have the SAP family 
proteins SAP and EAT-2.
26-28
  However, investigation of CD150 and CD84 KO mouse 
models revealed no overall effect on hemostasis, implying that their contribution to platelet 
function is minimal, and can be compensated for.
28,29
    
With the recent increase in the number of ITIM-containing receptors reported in 
platelets and their diverse functional roles in regulating platelet homeostasis, we compiled 
this review to summarize structural and functional features, landmark discoveries, 
controversies and intriguing new findings that dispel the notion of ITIM-containing receptors 
as simply inhibitors of ITAM-mediated signaling (Figure 4).  We focus on PECAM-1, G6b-B 
and TLT-1, which together illustrate the old, the new and the non-conventional members of 
this family of receptors in platelets. 
 
PECAM-1 – the prototype 
Structure and function 
PECAM-1 is expressed on the majority of non-erythroid hematopoietic cells, including 
platelets, monocytes, neutrophils, T cells, and B-cell subsets, as well as being highly 
expressed on vascular endothelial cells.
30
  This 130 kDa receptor has a large, highly 
glycosylated extracellular domain comprised of six immunoglobulin (Ig)-constant 2 (C2)-like 
domains, a transmembrane domain, and a cytoplasmic tail that conveys signaling 
functionality.  Alternative splicing of Pecam1 gives rise to a number of isoforms, with the 
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Δ15 isoform being the most prevalent in human platelets.  PECAM-1 undergoes trans-
homophilic interactions mediated by the two N-terminal IgC2-like domains, D1 and D2,
31,32
 
with particular dependence on Lys89
30
, and an intracellular component encoded by exon 14 
confers the capacity for heterophilic binding.  A recent crystallographic study has revealed 
how D1 and D2 permit homophilic interactions in both cis and trans, and also how sugar 
moieties are accommodated at the binding interface.
33
  Other factors, including receptor 
density, glycosylation and Ca
2+
, can all influence PECAM-1-ligand interactions.
34
  This 
interaction is likely to be of low affinity under resting conditions, as platelets do not adhere to 
each other or endothelial cells under healthy conditions, making platelet-platelet and platelet-
endothelial cell interactions during thrombus formation the probable physiologically relevant 
context.  Avidity and affinity are likely increased under these conditions.  In vivo thrombosis 
models support this hypothesis as platelet PECAM-1 serves to limit thrombus size,
35
 
discussed in detail below.  However, low affinity interactions under resting conditions cannot 
be discounted and may serve to strengthen inhibitory signals from PGI2 and NO.  
Heterophilic binding partners include the integrin αVβ3,
36
 neutrophil CD177
37
 and CD38,
38
 
which are reportedly relevant in the context of inflammation and cancer.  
Adjacent to the transmembrane domain of human PECAM-1 on the cytosolic side is a 
palmitoylation site (C595) followed by a proline-rich region (PRR), ITIM (Y663) and ITSM 
(Y686) – C594, Y662 and Y685, respectively, in murine PECAM-1 (Figure 3 and Table 2).  
Ligand engagement results in tyrosine phosphorylation of the ITIMs by SFKs, notably Lyn in 
platelets,
39
 leading to recruitment of Shp1 and Shp2.  The structure, phosphorylation and 
accessibility of these regions to binding partners are influenced by interactions with the 
plasma membrane.
40,41
   
The primary function of platelet PECAM-1 is to inhibit platelet activation and 
thrombosis at sites of vascular injury by attenuating signaling from the ITAM-containing 
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receptor complex GPVI-FcR -chain when it engages collagen.  This inhibition can however 
be overcome with high concentrations of GPVI agonists.
42
  Although less general and less 
robust than endothelial-derived PGI2 and NO,
43
 the inhibitory effect of PECAM-1, together 
with that of other ITIM-containing receptors, is likely to be highly relevant in the context of 
atherosclerosis, when loss of the healthy endothelium results in a reduction in the local 
concentration of both of these soluble mediators.  In addition to its recruitment of Shp1 and 
Shp2 to attenuate activating signals, there is evidence that PECAM-1 can sequester activating 
SH2 domain-containing proteins, including SFKs and the lipid kinase phosphatidylinositol 3-
kinase (PI3K).
44
  PECAM-1 also contributes to integrin IIb3 outside-in signaling,
45
 and to 
GPIb internalization in a IIb-dependent manner.
46
 
Our knowledge of how PECAM-1 modulates signaling and cell activity underpins 
much of what we know about ITIM-containing receptor signaling in platelets, and has 
expedited the characterization of new members of this family in this biological context. 
 
Mouse Models 
Studies using PECAM-1 KO (Pecam1
-/-
) mice have greatly enhanced our understanding of 
the physiological functions of PECAM-1.  Platelets isolated from Pecam1
-/-
 mice display 
potentiated aggregation, Ca
2+
 release and secretion in response to collagen, the GPVI-specific 
ligand collagen-related peptide (CRP) and thrombin.
17,43
  Paradoxically, platelets from 
Pecam1
-/- 
mice spread less well on a fibrinogen-coated surface and exhibit reduced clot 
retraction compared with control platelets, suggesting that PECAM-1 is a positive regulator 
of IIb3-mediated outside-in signaling.
45
  However, the mechanism underlying this 
potentiation of integrin-mediated responses in platelets remains unclear, only a reduction in 
focal adhesion kinase phosphorylation has been shown.  The observed phenotype could 
therefore simply be due to up-regulation of compensatory mechanisms that limit platelet 
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spreading on fibrinogen in the absence of PECAM-1.  Further work is needed to determine 
the exact role of PECAM-1 in regulating IIb3 signaling and function. 
These changes in platelet reactivity result in enhanced thrombus formation following 
laser- and ferric chloride-induced injury in mesenteric arterioles and carotid arteries of mice, 
respectively, with both onset of thrombus formation and thrombus stability being increased.
35
  
Use of bone marrow chimeric mice proved this to be primarily due to loss of platelet, rather 
than endothelial PECAM-1.
35
  In contrast, tail bleeding times were increased in Pecam1
-/-
 
mice, due to a loss of endothelial PECAM-1.
47
  This suggests both positive and negative roles 
of PECAM-1 in thrombosis and hemostasis, respectively, dependent upon the lineage of cell 
expression.  It should be noted that a separate study reported no difference in thrombus 
formation or bleeding between wild-type and Pecam1
-/-
 mice following photochemical-
induced injury of arterioles and venules and tail-bleeding assay.
48
   However, there is little if 
any collagen exposure in this thrombosis model, instead it is predominantly dependent upon 
reactive oxygen species-mediated damage of endothelial cells.
49
  In contrast, ferric chloride 
injury results in endothelial denudation and exposure of the basement membrane therefore 
increasing reliance upon GPVI-mediated platelet activation.
50
  Lack of standardization and 
variability between different models likely accounts for the discrepancies between studies,
51
 
but also highlights the specialized role of PECAM-1 in these processes.
43
  Regardless of these 
controversies, evidence clearly demonstrates a vital role for PECAM-1 in regulating platelet 
activation and function, involving both canonical and non-canonical ITIM-mediated signaling 
mechanisms. 
With regards to platelet turnover, Pecam1
-/-
 mice have normal platelet counts,
47,52
 but 
exhibit a delayed recovery following antibody-mediated platelet depletion, due to impaired 
platelet production from megakaryocytes in the bone marrow.
52
  This impairment is attributed 
to a lack of polarity of the leading edge of migrating megakaryocytes, mediated by the 
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polarized compartmentalization of stromal-derived factor-1 (SDF-1) chemokine receptor 
CXCR4, and increased adhesion to extracellular matrix proteins in vitro.
53
  As a consequence, 
PECAM-1-deficient megakaryocytes exhibit aberrant spatial distribution in the bone marrow 
following antibody-mediated platelet depletion.
52
   
The biological functions of PECAM-1 extend beyond that of simply regulating 
platelet and megakaryocyte function.  Numerous studies have highlighted the importance of 
PECAM-1 in a broad range of cell types, including endothelial cells, hematopoietic and 
immune cells,
54
 all of which contribute to the overall phenotype of Pecam1
-/-
 mice. 
 
G6b-B – more than just a platelet inhibitor 
Structure and function 
The identification of G6b-B came almost a decade after that of PECAM-1,
55
 and establishing 
its role in platelet function took a further 10 years.  Restricted to platelets and 
megakaryocytes, G6b-B is one of a number of predicted variants (A-E) that arise from 
differential splicing (Figure 5).  These are either transmembrane-containing (G6b-A and -B) 
or potentially secreted (G6b-C, -D and -E).
56
  G6b-A and -B are both expressed in human 
platelets and have identical extracellular and transmembrane domains, but only the -B 
isoform contains the consensus ITIM and ITSM.  Two other isoforms, G6b-F and -G, have 
been predicted, but are likely not expressed as they contain intronic sequences within an 
alternative C-terminus. 
All G6b isoforms have a single variable-type Ig-like (IgV) domain and are N-
glycosylated (one predicted site in humans and two in mice).
19,56,57
  Human G6b-B has a 
classical ITIM consensus sequence at the membrane proximal tyrosine (Y194) and an ITSM 
(Y220) at the C-terminus (Figure 5 and Table 2).  Two PRRs in the juxtamembrane region 
may provide docking sites for SH3 domain-containing proteins, but this remains to be 
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proven.  An inhibitory role for G6b-B was supported by the observation that phosphorylated 
G6b-B isolated from pervanadate-treated COS-7 cells co-immunoprecipitated with both Shp1 
and Shp2,
56
 interactions that have since been verified in both human and mouse 
platelets.
18,19,57,58
  Antibody-mediated cross-linking of G6b-B also promoted Shp1 
recruitment and attenuation of CRP- and ADP-induced platelet aggregation and Ca
2+
 
release.
18
 
In vitro assays showed G6b-B to bind the physiological anti-coagulant heparin with a 
predicted affinity of 30 nM,
59
 comparable to the heparin-anti-thrombin III interaction,
60
 
assuming a 15 kDa average molecular weight for heparin.  This interaction is unexpected as 
G6b-B lacks a heparin-binding consensus sequence.
59,61,62
  However, the ectodomain of 
G6b-B has a theoretical pI > 10, most likely giving it a positive charge at neutral pH, which 
may account for the interaction with highly negatively charged heparin.  Heparin is released 
by mast cells in the sub-endothelial matrix, and interacts with a variety of proteins, including 
plasma proteins, receptors and cytokines to modulate biological and physiological processes.  
The best known function of heparin is as a cofactor of antithrombin III, conferring a 1,000-
fold increase in its inhibitory function of thrombin.
63
  The physiological significance of the 
interaction of heparin with G6b-B remains to be determined. 
 
Mouse Models 
With the exception of glycosylation, both mouse and human G6b-B are very similar in terms 
of expression, amino acid sequence (71% identity, 79% similarity), tyrosine phosphorylation, 
and binding of Shp1 and Shp2.
57
  To determine the physiological function of G6b-B, 
constitutive and conditional KO mouse models (G6b
-/-
 and Pf4-Cre
+
;G6b
fl/fl
, respectively) 
were generated.
57,64
  Both were healthy, fertile and viable, with no overt growth or 
developmental abnormalities.  However, in line with in vitro observations,
65
 an inhibitory 
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role for G6b-B in regulating signaling from GPVI-FcR -chain and the hemi-ITAM-
containing podoplanin receptor CLEC-2 was found.
57
  
One of the most striking and unique features of G6b
-/-
 mice is a dramatic reduction in 
platelet counts.  This could be explained by a combination of reduced platelet recovery 
following antibody-mediated platelet depletion, supported by a reduction in G6b
-/-
 
megakaryocyte proplatelet formation, and enhanced platelet clearance, due to platelets being 
pre-activated and having surface antibodies bound, targeting them for destruction.
57
  
Together, these defects contributed to a 77% drop in platelet count.  It is unlikely these 
effects are due to loss of G6b-B expression in other cell types as G6b-B is highly lineage 
specific (Figure S1).
66
  This is supported by the fact that G6b constitutive and conditional KO 
mouse models exhibit the same phenotype.
57,64
  Platelet surface receptor levels were also 
altered to varying degrees in G6b
-/-
 mice,  particularly GPVI, which was reduced by 82% 
relative to platelets from control mice.  This was most likely attributable to increased receptor 
shedding mediated by the metalloproteinase ADAM10, which was increased by 36% in 
platelets from G6b
-/-
 mice. 
Collectively, platelet defects exhibited by G6b
-/-
 mice culminated in increased 
bleeding rather than a prothrombotic phenotype that would be expected when deleting an 
inhibitor of platelet activation.  Reduced platelet counts alone cannot fully explain the 
bleeding diathesis, as it has previously been shown that 80-90% reduction in platelet count 
has only mild bleeding and thrombotic consequences in mice.
67
  However, when combined 
with reduced reactivity to collagen and thrombin, as is the case in G6b
-/-
 mice, then increased 
bleeding is the outcome.  Collagen was still able to elicit a reduced aggregation and ATP 
secretion response, owing to increased avidity and signaling through simultaneous binding of 
GPVI and the integrin 21, whilst signaling via CLEC-2 was enhanced, validating G6b-B as 
a negative regulator of ITAM-containing receptor signaling.  This was further demonstrated 
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using Gp6
+/-
G6b
+/-
 mouse platelets, which hyper-responded to GPVI agonists, compared with 
platelets from Gp6
+/-
 mice that expressed comparable levels of GPVI.
57
  Interestingly, 
antibody-mediated depletion of CLEC-2 in addition to deletion of Gp6 only partially rescued 
the G6b
-/-
 phenotype,
57
 suggesting that G6b-B has additional undefined functions in 
megakaryocytes and platelets, independent of its inhibitory effect on ITAM-containing 
receptor signaling.  One such function is to positively regulate integrin-mediated spreading, 
identified by reduced ability of G6b
-/-
 megakaryocytes to spread on fibrinogen, collagen and 
fibronectin, and thrombin-stimulated G6b
-/-
 platelets to spread on fibrinogen.
57
  These studies 
highlight the complexity of G6b-B signaling and demonstrate a clear role for this receptor in 
platelet production and clearance that cannot be compensated for by other ITIM-containing 
receptors.  It should be noted that Shp1 and Shp2 conditional KO mice partially phenocopied 
G6b conditional KO mice,
64
 further supporting the hypothesis that these SH2 domain-
containing PTPs are pivotal effectors of G6b-B.  In addition, the recently described G6b-B 
diY/F knockin mouse model, in which tyrosine (Y) residues within ITIM and ITSM were 
mutated to phenylalanine (F) residues, uncoupling G6b-B from Shp1 and Shp2, recapitulated 
the G6b
-/-
 phenotype.
68
  
The physiological role of G6b-B has also now been validated in humans by Melhem 
and co-workers who characterized a family that exhibited an autosomal recessive 
thrombocytopenia.
69
  Whole exome sequencing identified a nonsense mutation at the codon 
for residue C108 of human G6b resulting in a stop codon (p.C108*) and protein instability in 
transiently transfected K562 cells.
69
  Patients exhibited severe thrombocytopenia, 
splenomegaly, increased number of megakaryocytes and fibrosis in bone marrow biopsies, 
similar to that reported in G6b KO and G6b-B diY/F mice.
57,68
  Interestingly, patients 
harboring this mutation were not reported to have a bleeding diathesis, whereas G6b
-/-
 mice 
did show increased bleeding in a tail injury model, suggesting subtle differences underlie the 
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phenotypes in humans and mice.  Although causes of these defects reported in both species 
can be varied, it is worth noting that mice expressing human G6b-B do not exhibit any of 
these defects,
70
 supporting the hypothesis that human and mouse G6b-B perform the same 
physiological functions and are critical regulators of platelet homeostasis. 
 
Signal transduction 
Considerable evidence exists to support the hypothesis that G6b-B is an important regulator 
of ITAM-containing receptor and integrin signaling, as well as platelet turnover.  Similar to 
other ITIM-containing receptors, the current understanding is that G6b-B mediates its actions 
largely through recruitment of Shp1 and Shp2 to the plasma membrane, but there may be 
additional contributions from interactions with other effectors.
58
  In a manner akin to the 
sequestration of Shp2/p85 complexes by PECAM-1,
44
 it is possible that G6b-B may compete 
for effectors of ITAM-containing receptor signaling under resting conditions to prevent 
spurious activation signals.
58
  However, these interactions have yet to be validated in platelets 
and the high affinity of G6b-B for Shp1 and Shp2 (nM range),
58
 strongly suggest these 
interactions are likely to dominate. 
Once recruited, PTPs are predicted to be activated and dephosphorylate key 
substrates, leading to an attenuation of tyrosine kinase signaling and cell activation.  
However, the stoichiometry and downstream effects are probably more nuanced.  
Interestingly, G6b-B is highly phosphorylated in resting platelets compared with other 
platelet ITIM-containing receptors.
19
  The significance of this is not yet known, but it 
suggests that G6b-B may be transmitting weak inhibitory signals even under resting 
conditions.   
The two PRRs in the juxtamembrane region of the cytoplasmic tail of human G6b-B 
may serve to provide spatiotemporal control of signal strength, onset or duration of signaling, 
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as seen with GPVI.  A pool of active SFKs can rapidly phosphorylate the GPVI-FcR -chain 
receptor following ligand engagement.  These SFKs are maintained in a primed state through 
the actions of the receptor-like PTP CD148,
71,72
 which dephosphorylates the inhibitory 
tyrosine residue in the C-terminal tail of SFKs.  Active Lyn and Fyn are constitutively 
associated with the GPVI membrane-proximal PRR via their SH3 domain.  This interaction is 
important for the kinetics of GPVI signaling,
73
 with loss of the PRR delaying the onset, but 
not extent, of signaling by GPVI.
74
  Intriguingly, Fyn, Src and Syk were shown to associate 
with phosphopeptides corresponding to the tandem ITIM/ITSM of G6b-B,
58
 possibly aiding 
regulation of Shp1 and Shp2 interaction and downstream signaling.  However, this has yet to 
be confirmed in platelets. 
Thus, the biological function of G6b-B extends beyond that of inhibiting ITAM-
containing receptor signaling in platelets (Figure 4).  Its potential for regulating platelet 
reactivity under resting conditions and apparent role in platelet production, coupled with 
specific megakaryocyte-platelet expression (Figure S1), offers a novel therapeutic approach 
for managing thrombotic and hemorrhagic risk.  It is likely that the elucidation of its 
endogenous ligand will greatly enhance our understanding of its function. 
 
TLT-1 – the non-conventional 
Structure/Function 
Initially identified as the inhibitory analogue of the triggering receptor expressed on myeloid 
cells-1 (TREM-1) family of immune receptors, TLT-1 is a type I single IgV-containing 
surface receptor with an intracellular ITIM and ITSM-like sequence (Figure 3 and Table 2).
75
  
Whilst TREM-1 recruits the ITAM-containing adaptor protein DAP12 via a positive lysine 
residue in its transmembrane domain,
76
 TLT-1 lacks this residue.  TLT-1 was hypothesized to 
negatively regulate TREM-1 activity, yet its expression in blood cells is restricted to 
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megakaryocytes and platelets,
20
 which have no detectable TREM-1 by proteomics-based 
approaches, raising the possibility of alternative functions.  TLT-1 is in fact the most 
abundant ITIM-containing receptor in human and mouse platelets, which are estimated to 
contain 14,200 and 154,769 copies per platelet by quantitative proteomics, respectively 
(Table 3).
26,27
  However, unlike other platelet ITIM-containing receptors, TLT-1 is localized 
specifically in α-granules in resting platelets, and is up-regulated on the surface following 
thrombin-mediated activation.
20
  Surprisingly, despite containing an ITIM and a non-
consensus ITSM (Table 2 and Figure 3), TLT-1 was found to have activating functions in a 
transiently transfected RBL-2H3 mast cell line, which showed enhanced FcRI-induced Ca2+ 
mobilization,
77
 while in platelets, antibody-mediated blocking of TLT-1 inhibits 
aggregation.
78
 
Platelet activation with thrombin results in the shedding of the ectodomain of TLT-1 
referred to as soluble TLT-1 (sTLT-1), which is a competitive inhibitor of TREM-1 and has 
anti-inflammatory properties.
79
  Indeed, sTLT-1 levels were substantially elevated in plasma 
from septic patients compared with healthy individuals, correlating with disseminated 
intravascular coagulation associated with sepsis.
80
  Recombinant protein comprised solely of 
the ectodomain of TLT-1 was found to augment platelet aggregation and also to bind 
fibrinogen, suggesting fibrinogen is the physiological ligand of membrane bound TLT-1.
80
 
 
Signal transduction 
Phosphorylation of Y230 in the ITSM-like domain and Y266 in the ITIM of human TLT-1 is 
required for downstream signaling, the latter being critical for Shp2 recruitment in 
transiently-transfected pervanadate-treated RBL-2H3 cells.
77
  An interaction with Shp1 was 
demonstrated in transiently transfected HEK293 cells upon discovery of the receptor,
75
 but 
this was not verified by others.
77,80
  Shp1 and Shp2 interactions have not been validated in 
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platelets, but pull-down assays using the cytoplasmic tail of the receptor did show an 
interaction with the ezrin/radixin/moesin (ERM) proteins in HEK293 and COS7 cells.  The 
moesin interaction was also identified in human platelets by immunoprecipitation of full 
length TLT-1.
80
  The ERM family links membrane proteins to the actin cytoskeleton and 
have important roles in lymphocyte activation and cytoskeleton remodeling during 
migration.
81
  Interestingly, TLT-1 contributes to early actin polymerization,
82
 indicating the 
ERM interaction may help to promote platelet activation.  Thus, signaling via TLT-1 is 
distinct to that of other platelet ITIM-containing receptors. 
 
Mouse Models 
The KO mouse model of TLT-1 (Treml1
-/-
) revealed a critical role for this receptor in 
dampening the inflammatory response and facilitating platelet aggregation at sites of vascular 
injury.
80
  This work confirmed an activating role for TLT-1 in platelets, notably aggregation 
responses to thrombin, collagen, ADP and U46619 were reduced, as was binding to 
fibrinogen, with a concomitant increase in tail bleeding times.
80
  This is partially mediated by 
fibrinogen binding and TLT-1 linking to the platelet cytoskeleton, and presumably also by 
facilitating activation signals through an undefined mechanism.  TLT-1-deficient mice also 
exhibit a 20% reduction in platelet count, suggesting a role in platelet production and/or 
clearance.
80
  Lipopolysaccharide (LPS)-treated Treml1
-/-
 mice developed higher plasma levels 
of TNF and D-dimer compared with control mice and were more likely to succumb to LPS 
challenge, correlating with elevated levels of sTLT-1 in septic patients.
80
  Despite the major 
advances in our understanding of the pathophysiological functions of TLT-1, several key 
questions remain, including the functional role of TLT-1 in platelets and megakaryocytes, 
how it signals and whether platelet TLT-1 regulates leukocyte localization and function. 
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Other ITIM-containing receptor contributors 
In addition to PECAM-1, G6b-B and TLT-1, several other ITIM-containing receptors have 
been shown to regulate platelet activation and thrombus formation (Table 1).  CEACAM1 
and CEACAM2 are expressed on a variety of tissues, including platelets (Figure S1),
66
 and 
get upregulated on the surface of activated platelets, suggesting intracellular pools.
21,22
  
Findings from KO mouse models showed that both CEACAM1 and CEACAM2 attenuate 
ITAM receptor-mediated responses, presumably via Shp1 and Shp2, but paradoxically 
positively regulate integrin-mediated responses,
21,22,83,84
 a recurring theme for platelet ITIM-
containing receptors.  Larger and more stable thrombi following ferric chloride injury in vivo 
was also demonstrated in CEACAM1- and CEACAM2-deficient mice, indicating that the net 
functions of CEACAM1 and CEACAM2 is to limit thrombus growth.  Platelet counts were 
normal in both CEACAM1- and CEACAM2-deficient mice, suggesting they are not required 
for platelet production and/or turnover under normal conditions.  It would be interesting to 
determine whether deletion of both receptors has additive or synergistic effects on platelet 
activation and thrombosis phenotypes observed in single KO mice.  However, the close 
proximity of the Ceacam1 and Ceacam2 genes on chromosome 7, makes generation of 
double-deficient mice technically challenging.
85
  Controversially, CEACAM1 is not detected 
in human platelets by proteomics-based approaches and at low copy number in mouse 
platelets (868 copies per platelet).  CEACAM2, found only in the murine genome, was also 
not detected in mouse platelets (Table 3).
26,27,86
  The reason for this discrepancy is not known, 
but may simply be a reflection of low abundance, masking of peptides during mass 
spectrometry or misassignment of peptides to other proteins following detection.
87
  
LILRB2 (also referred to as PIR-B) is the most recent addition to the platelet ITIM-
containing receptor family, and transgenic mice lacking the intracellular tail are uniquely 
thrombocythemic.
23
  Platelet aggregation and signaling was mildly enhanced in response to 
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CRP, again supporting a role in negatively regulating ITAM receptor signaling.  It is 
noteworthy that PIR-B is not detected in either human or mouse platelets by proteomics-
based approaches,
26,27
 possibly due to low abundance, but raising questions about the platelet 
phenotype of PIR-B KO mice.  Observed phenotypes may arise from indirect effects of 
ablating PIR-B in other lineages and impacting platelet production.  This in fact applies to 
most of the constitutive ITIM receptor KO and transgenic mouse models studied to date as all 
are expressed in other lineages, with the exception of G6b-B and TLT-1, which are highly 
megakaryocyte/platelet-specific (Figure S1).
66
  Alternatively, because transcripts for all of 
these receptors are detected in the megakaryocyte lineage, observed platelet phenotypes may 
be due to defects in platelet production, or transfer of activating signals to platelets, as is the 
case in LAIR1 KO mice,
25
 regardless of expression of the ITIM-containing receptor in 
platelets. 
 
Summary 
Platelets and megakaryocytes express an array of ITIM-containing receptors that vary in their 
abundance, structure and functional significance.  KO and transgenic mouse models have 
been pivotal in establishing physiological functions of these receptors in the megakaryocyte 
lineage, but much remains to be explored.  Despite all platelet ITIM-containing receptors 
interacting with Shp1 and Shp2, phenotypic analysis of mouse models are dramatically 
different and indicate additional roles beyond exclusively inhibiting ITAM receptor signaling 
(Figure 4).  It is likely that there exists a spatiotemporal regulation system that governs 
receptor and effector availability and interaction, and that this system shapes distinct 
functional outputs.  Shp1 and Shp2 are clearly major players in mediating the biological 
functions of ITIM-containing receptors in platelets, but the stoichiometry of binding and 
target specificity of these PTPs downstream of individual ITIM-containing receptors remains 
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to be determined.  In addition, an activatory role in IIb3 signaling, a temporally distinct 
event from signaling by GPVI-FcR -chain and CLEC-2, has been described for PECAM-1, 
G6b-B and CEACAM1/2.  The mechanism by which these receptors facilitate integrin 
signaling remains to be determined.  How TLT-1 acts as a positive regulator of platelet 
activation also has yet to be elucidated.  A considerable amount of work remains to fully 
comprehend how ITIM-containing receptors work in concert with ITAM-containing 
receptors and integrins to orchestrate platelet reactivity and appropriate responses following 
injury, and how this may be overruled in pathological circumstances.   
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Table 1. Summary of mouse platelet ITIM-containing receptors 
Receptor Characteristics Mouse models Signaling References 
PECAM-1 
(CD31) 
Expression: non-erythroid hematopoietic cells, 
endothelium 
Isoforms: various, 15 most prevalent in human 
platelets 
MW: 130kDa 
Ectodomain: six IgC2-like domains, glycosylated 
Ligands: trans-homophilic, CD177, CD38, v3 
Intracellular motifs: palmitoylation (C594), PRR, 
ITIM (Y662), ITSM (Y685)  
Interactions: Shp1, Shp2, SHIP1, p85 (PI3K), Lyn 
Constitutive knock-out 
Platelet count: normal, delayed recovery following 
depletion 
Platelet volume: normal 
Receptor levels: normal 
Functional responses:  collagen, thrombin 
aggregation 
Integrin function:  spreading on fibrinogen,  clot 
retraction 
Hemostasis:  tail bleeding 
Thrombosis:  onset, size, stability in laser and 
ferric chloride injury models 
Attenuates ITAM, thrombin and integrin 
receptor signaling 
 
  phosphorylation, Shp1 and Shp2 
interaction to collagen, thrombin, fibrinogen 
and anti-PECAM-1 antibody stimulation 
17, 30, 36, 
37, 38, 39, 
42, 44, 45, 
47 
G6b-B Expression: megakaryocyte and platelet specific 
Isoforms: membrane associated (-A and -B) and 
predicted secreted (-C, -D and -E) 
MW: 24-30kDa doublet, glycosylated 
Ectodomain: single IgV-like domain 
Ligands: heparin 
Intracellular motifs: PRR, ITIM (Y195), ITSM 
(Y221) 
Interactions: Shp1, Shp2, (Syk, PLC2 – only by 
SPR), Fyn>Src 
Constitutive and Pf4-Cre knock-out 
Platelet count:  77%, increased clearance and 
reduced production 
Platelet volume:  38%  
Receptor levels:  80% GPVI, minor  2, GPIb 
and CLEC-2,  ADAM-10 
Functional responses:  GPVI aggregation,   
CLEC-2 aggregation, thrombin aggregation 
reversible 
Integrin function:  platelet spreading on 
fibrinogen  with thrombin pre-activation,  
megakaryocyte spreading on fibrinogen, fibronectin 
and collagen  
Hemostasis:  tail bleeding 
Thrombosis: unknown 
Attenuates GPVI- and ADP-induced 
aggregation and Ca
2+
 release 
 
 basal Syk phosphorylation (pY519/20) in 
G6b
-/-
 platelets 
 
Basally phosphorylated 
 
  phosphorylation, Shp1 and Shp2 
interaction to CRP and thrombin 
56, 57, 58, 
59, 64 
TLT-1 Expression: megakaryocyte and platelet specific  
Isoforms: sTLT-1 (shed extracellular domain) 
MW: 38kDa 
Ectodomain: single IgV-like domain 
Ligands: fibrinogen 
Intracellular motifs: palmitoylation (C188), PRR, 
ITIM (Y266) 
Interactions: Shp1, Shp2, ERM proteins 
Constitutive knock-out 
Platelet count:  20% 
Platelet volume: unknown 
Receptor levels: unknown 
Functional responses:  ADP and U46619 
aggregation, delayed collagen and thrombin 
aggregation 
Integrin function:  fibrinogen binding  with ADP 
stimulation 
Thrombosis: unknown 
Hemostasis:  tail bleeding 
Other:  systemic inflammatory response to LPS 
Augments platelet aggregation to multiple 
agonists 
 
Associates with ERM proteins potentially 
linking fibrinogen to the cytoskeleton 
20, 75, 77, 
78, 80 
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CEACAM1 
(Bgp-1) 
Expression: immune, hematologic, epithelial and 
endothelial cells 
Isoforms: most dominant is CEACAM1L-4L (4 
denotes the number of IgG domains, L denotes the long 
intracellular domain that contains the ITIMs) 
MW: 160kDa, heavily glycosylated 
Ectodomain:  one IgV-like domain and three IgC2-like 
domains  
Ligands: homophilic 
Intracellular motifs: ITIMs (Y454) ITSM (Y481), 
PRR 
Interactions: Shp1, Shp2 
Constitutive knock-out 
Platelet count: normal 
Platelet volume: unknown 
Receptor levels: normal 
Functional responses:  GPVI aggregation, granule 
release and flow adhesion  
Integrin function:  platelet spreading on 
fibrinogen,  clot retraction 
Hemostasis:  tail bleeding 
Thrombosis: form larger, more stable thrombi 
Attenuates GPVI and CLEC-2 mediated 
platelet activation – potentially via PLC2 
 
Direct association and implicated in 
regulating function of IIb3 
21, 83 
CEACAM2 
(Bgp-2) 
Expression: platelets, intestinal tissue crypt epithelia, 
kidney, testis and several brain nuclei 
Isoforms: most dominant in platelets is CEACAM2-2L  
MW: 52kDa, glycosylated 
Ectodomain: one IgV-like domain and one IgC2-like 
domain 
Ligands: coronavirus mouse hepatitis virus spike 
glycoproteins 
Intracellular motifs: ITIM (Y273), PRR, ITSM 
(Y300) 
Interactions: Shp1, Shp2 
Constitutive knock-out 
Platelet count: normal 
Platelet volume: unknown 
Receptor levels: normal 
Functional responses:  GPVI aggregation, granule 
release and flow adhesion,  CLEC-2 aggregation  
Integrin function:  platelet spreading on 
fibrinogen,  clot retraction  
Hemostasis:  tail bleeding 
Thrombosis: form larger, more stable thrombi 
 
Attenuates GPVI and CLEC-2 mediated 
platelet activation  
 
Augmented phosphorylation of PLC2, Src 
and Syk in response to CRP and rhodocytin 
in ceacam2
-/-
 platelets  
22, 84 
PIR-B 
(LILRB2) 
Expression: platelets, immune cells (monocytes, 
macrophages and dendritic cells), hematopoietic cells 
and neurons 
Isoforms: Seven members 
MW: 125kDa, glycosylated 
Ectodomain: six IgC2-like domains, glycosylated 
Ligands: angiopoietin-like protein 2 (ANGPLT2) 
Intracellular motifs: ITIM (Y770), PRR 
Interactions: Shp1, Shp2 
Deletion of intracellular tail 
Platelet count:  47% 
Platelet volume: unknown 
Receptor levels: unknown 
Functional responses:  GPVI aggregation and 
granule release,  ADP and thrombin aggregation  
Integrin function:  platelet spreading on 
fibrinogen  
Hemostasis: unknown 
Thrombosis: unknown 
Attenuates collagen, thrombin and ADP 
induced platelet activation  
 
Attenuates Syk and FcR signaling upon 
antibody mediated cross-linking in immune 
cells 
 
ANGPLT2 attenuates GPVI-induced 
phosphorylation of LAT, SLP76, and PLC2 
partially via PIR-B 
23, 88 
MW, molecular weight (Western blotting); Ig C2, immunoglobulin constant-2; PRR, proline-rich region; PI3K, phosphoinositide 3-kinase; Ig V, 
immunoglobulin variable; Pf4-Cre, platelet factor 4 promotor driven Cre-recombinase transgenic mouse. Residues are numbered according to the 
mature mouse protein after cleavage of the signal peptide. 
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Table 2.  Megakaryocyte/platelet ITIM and ITSM receptor sequences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ITIM, immunoreceptor tyrosine-based inhibition motif (consensus: I/V/LxYxxL/V); ITSM, immunoreceptor tyrosine-based switch motif  
(consensus: TxYxxV/I).  Tyrosine residues are numbered according to the mature protein after cleavage of the signal peptide. 
 
 
  
Receptor 
 Human   Mouse  
ITIM ITSM 
Non-consensus 
ITIM/ITSM 
ITIM ITSM 
Non-consensus 
ITIM/ITSM 
PECAM-1 VQY663TEV TVY686SEV  VEY662TEV TVY685SEI  
G6b-B LLY194ADL TIY220AVV  LHY195ADL TVY221AVV  
TLT-1 VTY266ATV  TTY230TSL VTY266ATV  SIY232TGS 
CEACAM1 VTY459STL 
IIY486SEV 
  VAY454TVL TVY481SEV  
CEACAM2     VAY273TVL TVY300SEV  
LILRB2 
(PIR-B) 
VTY541AQL  NLY512AAV 
SIY571ATL 
VTY770AQL  SLY689ASV 
TEY746EQA 
SVY800ATL 
LAIR-1 VTY230AQL 
ITY260AAV 
  VTY207IQL STY236AAI  
CD84  TIY258TYI  
TVY295SEV 
  TVY244AVV 
TIY279SSV 
 
CD150  TIY261AQV 
TVY307ASV 
TIY287VAA  TIY264AQV 
TVY311ASV 
TIY291VAA 
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Table 3.  Platelet ITIM- and ITSM-containing receptor protein and RNA expression levels 
 
 
 
 
 
 
 
 
Protein expression - estimated protein copy numbers per platelet in human
27
 and mouse
26
 quantitative proteomic studies; Gene expression – mean 
RPKMs (reads per kilobase of exon model per million mapped reads) values in human and mouse platelet quantitative transcriptomic studies
86
; N/A - 
gene not present in that species  
Receptor 
Human Mouse 
Protein 
expression 
Gene 
expression 
Protein 
expression 
Gene 
expression 
PECAM-1 9400 42.45 5566 358.61 
G6b-B 13700 638.61 29637 54.31 
TLT-1 14200 568.68 154769 1118.59 
CEACAM1 not detected 0.01 868 45.21 
CEACAM2 N/A N/A not detected 0.41 
LILRB2 
(PIR-B) 
not detected 0.63 not detected 0 
LAIR-1 not detected 0.88 not detected 0 
CD84 2900 7.60 9261 421.64 
CD150 not detected 0.07 21750 312.32 
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Figure Legends 
Figure 1.  Inhibition of platelet activation by cyclic nucleotide generation.  Prostacyclin 
(PGI2) and nitric oxide (NO) activation of cyclic nucleotide generation providing generalized 
inhibition of platelet activation. 
Figure 2.  Classical inhibitory function of ITIM-containing receptors.  Inhibition of ITAM-
containing receptor signaling through the recruitment of the phosphatases Shp1, Shp2 or 
SHIP1. 
Figure 3.  Platelet ITIM-containing receptors.  Main structural features are shown, including 
extracellular IgC2-like and IgV-like domains and the main intracellular signaling motifs, 
namely ITIMs (consensus sequence I/V/LxYxxL/V), ITSMs (TxYxxV/I) and PRRs (PxxP) 
along with non-consensus ITIM/ITSM-like tyrosine residues.  All receptors have been 
described in platelets with the exception of LAIR-1, which is only found in megakaryocytes.  
Residues are numbered according to mature mouse peptide sequences, following cleavage of 
the signal peptide. 
Figure 4.  Classical and putative functions of ITIM-containing receptors.  Increasing 
evidence is implicating ITIM-containing receptors as more than just inhibitors of ITAM-
containing receptors, particularly as positive regulators of integrin-mediated functions.  
Potential roles in regulating cytoskeletal remodeling and G protein-coupled receptor (GPCR) 
signaling warrant further investigation. 
Figure 5.  Established and putative isoforms of human G6b.  Main structural features are 
shown, including the IgV domain, ITIM, ITSM and PRR.  G6b-A and -B contain 
transmembrane regions and are therefore represented as surface receptors.  G6b-C, -D and -E, 
identified in transcriptome analysis but not as expressed protein, are predicted to be secreted 
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as they lack the transmembrane domain.  Residues are numbered according to mature human 
peptide sequences, following cleavage of the signal peptide. 
Figure S1.  Gene-expression profile of platelet ITIM-containing receptors across major 
hematopoietic cell types in mice from Haemosphere database.  Haemosphere 
(http://haemosphere.org/) online database was used to search Haemopedia dataset for (A) 
Pecam1, (B) G6b, (C) Treml1, (D) Ceacam1, (E) Ceacam2, (F) Pirb and (G) Lair1 gene 
expression in primary murine hematopoietic cells.
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  Abbreviations: PreCFUE, PreColony 
forming unit - erythroid;  MEP, Megakaryocyte Erythrocyte Progenitor;  CFUE, Colony 
forming unit - erythroid;  EryBlPB, Polychromatic erythroblasts (some Basophillic 
erythrobklasts);  EryBlPO, Polychromatic erythroblasts (some Orthochromatic erythroblasts);  
Retic, Reticulocytes;  Meg8N, 8N Megakaryocytes;  Meg16N, 16N Megakaryocytes;  
Meg32N, 32N Megakaryocytes;  Mast, Mast Cells;  Baso, Basophils;  EoP, Eosinophil 
Progenitor;  Eo, Naive Eosinophil;  NeutLN, Neutrophils from the lymph nodes;  NeutPt, 
Neutrophils from the peritoneal cavity;  MonoPB, Monocytes from the peripheral blood;  
MonoLN, Monocytes from the lymph nodes;  Mac, Macrophage;  CDP, Common DC 
Precursor;  cDC1, Conventional Dendritic Cell 1;  cDC2, Conventional Dendritic Cell 2;  
MigDC, CD205+ Migratory Dendritic Cell;  ProB, B Cell Progenitor;  PreB, B Cell 
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Figure S1.  Gene-expression profile of platelet ITIM-containing receptors across major 
hematopoietic cell types in mice from Haemosphere database.  Haemosphere 
(http://haemosphere.org/) online database was used to search Haemopedia dataset for (A) 
Pecam1, (B) G6b, (C) Treml1, (D) Ceacam1, (E) Ceacam2, (F) Pirb and (G) Lair1 gene 
expression in primary murine hematopoietic cells.
66
  Abbreviations: PreCFUE, PreColony 
forming unit - erythroid;  MEP, Megakaryocyte Erythrocyte Progenitor;  CFUE, Colony 
forming unit - erythroid;  EryBlPB, Polychromatic erythroblasts (some Basophillic 
erythrobklasts);  EryBlPO, Polychromatic erythroblasts (some Orthochromatic erythroblasts);  
Retic, Reticulocytes;  Meg8N, 8N Megakaryocytes;  Meg16N, 16N Megakaryocytes;  
Meg32N, 32N Megakaryocytes;  Mast, Mast Cells;  Baso, Basophils;  EoP, Eosinophil 
Progenitor;  Eo, Naive Eosinophil;  NeutLN, Neutrophils from the lymph nodes;  NeutPt, 
Neutrophils from the peritoneal cavity;  MonoPB, Monocytes from the peripheral blood;  
MonoLN, Monocytes from the lymph nodes;  Mac, Macrophage;  CDP, Common DC 
Precursor;  cDC1, Conventional Dendritic Cell 1;  cDC2, Conventional Dendritic Cell 2;  
MigDC, CD205+ Migratory Dendritic Cell;  ProB, B Cell Progenitor;  PreB, B Cell 
Precursor;  ImmB, Immature B Cell;  B1, B1 B Cell;  B2, B2 B Cell;  MatB, Mature B Cell;  
CD4TThy1lo, Early Intrathymic CD4lo Precursor;  TN1, Triple Negative Thymocyte 1;  
TN2, Triple Negative Thymocyte 2;  TN3, Triple Negative Thymocyte 3;  TN4, Triple 
Negative Thymocyte 4;  DblPosT, Double positive thymocytes;  NveCD4T, Naive CD4 T 
Cell;  NveCD8T, Naive CD8 T Cell;  EffCD4T, Effector Memory CD4 T Cells;  EffCD8T, 
Effector CD8 T cells;  CD4TLN, CD4 T Cell;  CD8TLN, CD8 T Cell;  RegT, Regulatory T 
Cell;  MemCD8T, Memory CD8 T;  NK, Resting NK cells. 
 
